Jing Lv
AstraZeneca
8 Papers
10 Citations
Jing Lv is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer & Carcinoma. The author has an hindex of 6, co-authored 8 publications.
Chat about Author
Papers
Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets
Ziliang Qian,Guanshan Zhu,Lili Tang,Mei Wang,Lianhai Zhang,Jiangang Fu,Chunlei Huang,Shuqiong Fan,Yun Sun,Jing Lv,Hua Dong,Beirong Gao,Xinying Su,De-Hua Yu,Jie Zang,Xiaolin Zhang,Jiafu Ji,Qunsheng Ji +17 more
TL;DR: Wang et al. as mentioned in this paper conducted a comprehensive whole-genome analysis of 131 Chinese gastric cancer tissue specimens using wholegenome array comparative genomic hybridization, which revealed gene focal amplifications, including CTSB, PRKCI, PAK1, STARD13, KRAS, and ABCC4, in addition to ERBB2, FGFR2, and MET.
69
Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models.
Xian-hua Wu,Jingchuan Zhang,Ruheng Zhen,Jing Lv,Li Zheng,Xinying Su,Guanshan Zhu,Paul R. Gavine,Song-Tao Xu,Shaohua Lu,Jun Hou,Yalan Liu,Chen Xu,Yunshan Tan,Liang Xie,Xiaolu Yin,Deming He,Qunsheng Ji,Yingyong Hou,Di Ge +19 more
TL;DR: This study demonstrates Trastuzumab-induced tumor regressions in HER-2 positive tumors, and highlights PIK3CA mutation as a potential resistance mechanism to Trastzumab treatment in pre-clinical patient-derived EC xenograft models.
Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models
Hao Chen,Qingqing Ye,Jing Lv,Peng Ye,Yun Sun,Shuqiong Fan,Xinying Su,Paul R. Gavine,Xiaolu Yin +8 more
TL;DR: Investigation of trastuzumab anti-tumor efficacy and its correlation with HER-2 status in primary xenograft models derived from Chinese patients with gastric adenocarcinoma found a high degree of histological and molecular similarity between the PDGAX mouse models and their corresponding patients’ gastricAdenocARCinoma tissues.
Abstract 928: Volitinib (HMPL504), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer.
Paul R. Gavine,Shiming Fan,Haihua Fu,Lu Han,Yuan Jie Liu,Jing Lv,Weiguo Qing,Yongxin Ren,Weiguo Su,Xinying Su,Huiying Wang,Liang Xie,Shirlian Xu,Wen Xu,Xiaolu Yin,Yongjuan Yu,Tianwei Zhang,Q. May Wang +17 more
TL;DR: Volitinib (HMPL504), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer.
3
Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Jinqiang Zhang,Lingli Zhang,Yumei Yan,Shaorong Li,Liang Xie,Wei Zhong,Jing Lv,Xiuhua Zhang,Yu Bai,Ziqiang Cheng +9 more
TL;DR: The results suggest that CNS penetration of 5-FU and lapatinib are not desirable and development of a true CNS penetrable therapeutic agent will further improve the response rate for BCBM.